Navigation Links
Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
Date:2/12/2008

e of unanticipated events.

Where to find additional information about the Transaction

Cellegy intends to file a registration statement and proxy statement in connection with the proposed transaction. Investors and stockholders are urged to read the registration statement and proxy statement when it becomes available because it will contain important information about the transaction. Additional information is also available in a Report on Form 8-K filed by Cellegy relating to the transactions described in this press release. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, CELLEGY'S STOCKHOLDERS ARE URGED TO READ THE PROXY STATEMENT REGARDING THE PROPOSED TRANSACTION CAREFULLY AND IN ITS ENTIRETY WHEN IT BECOMES AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and stockholders may obtain free copies of the registration statement and proxy statement and other relevant documents (when they become available) and other documents filed with the Securities and Exchange Commission at the Securities and Exchange Commission's web site at: http://www.sec.gov. In addition, investors and stockholders may obtain free copies of the documents filed with the Securities and Exchange Commission by Cellegy by contacting the persons identified below. Cellegy's directors and executive officers may be deemed to be participants in the solicitation of proxies from its stockholders in connection with the proposed transaction. Information regarding the interests of directors and executive officers in the transaction will be included in the proxy statement of the company. Additional information regarding directors and executive officers of Cellegy is also included in the company's annual report on Form 10-K for the year ended December 31, 2006 and, when it becomes available, its annual report on form 10-K for the year ended December 31, 2007, filed with the Securities and Exchange Com
'/>"/>

SOURCE Cellegy Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
3. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
4. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
6. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
7. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
8. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. SGX Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 3New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3
Breaking Biology News(10 mins): Killer catfish? Venomous species surprisingly common, study finds 2Copying mother nature's designs 2University of Washington professor garners Avanti Young Investigator Award 2Individuals Who Apply Pesticides Are Found to Have Double the Risk of Blood Disorder 48790 1Individuals Who Apply Pesticides Are Found to Have Double the Risk of Blood Disorder 48790 2Individuals Who Apply Pesticides Are Found to Have Double the Risk of Blood Disorder 48790 3Individuals Who Apply Pesticides Are Found to Have Double the Risk of Blood Disorder 48790 4Acoustiblok Inc Combines Sound Abatement and Insulation Materials at Broward County Waste to Energy Plant to Reduce Industrial Noise Pollution 48788 1Acoustiblok Inc Combines Sound Abatement and Insulation Materials at Broward County Waste to Energy Plant to Reduce Industrial Noise Pollution 48788 2Acoustiblok Inc Combines Sound Abatement and Insulation Materials at Broward County Waste to Energy Plant to Reduce Industrial Noise Pollution 48788 3Acoustiblok Inc Combines Sound Abatement and Insulation Materials at Broward County Waste to Energy Plant to Reduce Industrial Noise Pollution 48788 4Acoustiblok Inc Combines Sound Abatement and Insulation Materials at Broward County Waste to Energy Plant to Reduce Industrial Noise Pollution 48788 5MedThink Communications Wins Two Communicator Awards for Its Health Care Web Site Design 48786 1MedThink Communications Wins Two Communicator Awards for Its Health Care Web Site Design 48786 2